Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization

J Med Chem. 2015 Feb 12;58(3):1281-97. doi: 10.1021/jm501504k.

Lele Zhao ¹, Yingqing Wang, Danyan Cao, Tiantian Chen, Qi Wang, Yanlian Li, Yechun Xu, Naixia Zhang, Xin Wang, Danqi Chen, Lin Chen, Yue-Lei Chen, Guangxin Xia, Zhe Shi, Yu-Chih Liu, Yijyun Lin, Zehong Miao, Jingkang Shen, Bing Xiong

Affiliations

Affiliation

1 Department of Medicinal Chemistry, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, ‡Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, and §Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences , 555 Zuchongzhi Road, Shanghai 201203, China.

PMID: 25559428 DOI: 10.1021/jm501504k

Abstract

The signal transduction of acetylated histone can be processed through a recognition module, bromodomain. Several inhibitors targeting BRD4, one of the bromodomain members, are in clinical trials as Anticancer drugs. Hereby, we report our efforts on discovery and optimization of a new series of 2-thiazolidinones as BRD4 inhibitors along our previous study. In this work, guided by crystal structure analysis, we reversed the sulfonamide group and identified a new binding mode. A structure-activity relationship study on this new series led to several potent BRD4 inhibitors with IC50 of about 0.05-0.1 μM in FP binding assay and GI50 of 0.1-0.3 μM in cell based assays. To complete the lead-like assessment of this series, we further checked its effects on BRD4 downstream protein c-Myc, investigated its selectivity among five different bromodomain proteins, as well as the metabolic stability test, and reinforced the utility of 2-thiazolidinone scaffold as BET bromodomain inhibitors in novel Anticancer drug development.

Name
Email *

	Sorry, but the email address you supplied was invalid.